Kymera Therapeutics, Inc. 2026 Q1 – Outcomes – Earnings Name Presentation (NASDAQ:KYMR) 2026-05-04
Q1: 2026-04-30 Earnings AbstractEPS of -$0.71 beats by $0.15 | Income of $34.37M (55.50% Y/Y) beats by $26.14MThis text was written...
Therapeutics
BioXcel Therapeutics, Inc. (BTAI) Dialogue of Managing Acute Agitation in Schizophrenia and Bipolar Problems at Dwelling Transcript
Vimal MehtaFounder, CEO, President, & Director Good morning, everybody, and thanks for becoming a member of us immediately. I want...
Medicenna Therapeutics Corp. (MDNA:CA) Discusses New Scientific Knowledge From ABILITY-1 Research Evaluating MDNA11 in Most cancers Immunotherapy Transcript
Operator Welcome to Medicenna Therapeutics KOL Webinar. As a reminder, this convention name is being recorded. When you've got any...
Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Convention 2025 Transcript
ObservePlay Earnings NamePlay Earnings Name Aligos Therapeutics, Inc. (ALGS) Jefferies London Healthcare Convention 2025 November 17, 2025 10:00 AM EST...
Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley twenty third Annual World Healthcare
ObservePlay Earnings NamePlay Earnings NameViking Therapeutics, Inc. (NASDAQ:VKTX) Morgan Stanley twenty third Annual World Healthcare Convention September 8, 2025 3:20...
Aardvark Therapeutics, Inc. (AARD) Cantor Fitzgerald International Healthcare 2025 Transcript
ObservePlay Earnings NamePlay Earnings NameAardvark Therapeutics, Inc. (NASDAQ:AARD) Cantor Fitzgerald International Healthcare Convention 2025 September 3, 2025 11:30 AM EDT...
Akero Therapeutics: Cirrhosis Reversal Knowledge Derisks The Inventory (NASDAQ:AKRO)
This text was written byComply withAvisol Capital Companions is made up of a staff of medical specialists, finance professionals and...
Summit Therapeutics: Most cancers Drug With Nice Potential On ‘Quick Observe’ To US Market (SMMT)
This text was written byComply withEdmund Ingham is a biotech guide. He has been overlaying biotech, healthcare, and pharma for...
Camp4 Therapeutics Targets IPO On Early Optimistic Outcomes (CAMP)
This text was written byComply withDonovan Jones is a analysis specialist with 15 years of expertise figuring out alternatives for...
